Table 1.
Demographic and Clinical Characteristics of the Study Population at Baseline
| Placebo | Remdesivir | |||
|---|---|---|---|---|
| Included (n = 319) | Total (n = 516) | Included (n = 323) | Total (n = 532) | |
| Age, y, median (IQR) | 59 (47-68) | 60 (49-70) | 59 (48-69) | 59 (49-69) |
| Male sex | 205 (64.26) | 328 (63.57) | 210 (65.02) | 347 (65.23) |
| Race and ethnicity | ||||
| Asian | 30 (9.40) | 56 (10.85) | 42 (13.00) | 79 (14.85) |
| Black or African American | 84 (26.33) | 114 (22.09) | 73 (22.60) | 105 (19.74) |
| White | 167 (52.35) | 286 (55.43) | 168 (52.01) | 273 (51.32) |
| Ethnicity: Hispanic or Latino | 69 (21.63) | 114 (22.09) | 89 (27.55) | 132 (24.81) |
| Clinical characteristics | ||||
| Any comorbidities | 255 (79.94) | 417 (80.81) | 271 (83.90) | 435 (81.77) |
| Days of symptoms, median (IQR) | 9 (7-13) | 9 (7-13) | 9 (6-12) | 9 (6-12) |
| Baseline ordinal scale a | ||||
| 4 | 38 (11.91) | 63 (12.21) | 39 (12.07) | 75 (14.10) |
| 5 | 114 (35.74) | 202 (39.15) | 148 (45.82) | 231 (43.42) |
| 6 | 56 (17.55) | 98 (18.99) | 42 (13.00) | 94 (17.67) |
| 7 | 111 (34.80) | 153 (29.65) | 94 (29.10) | 132 (24.81) |
| Disease severity subgroups b | ||||
| Moderate/severe | 152 (47.65) | 265 (51.36) | 187 (57.89) | 306 (57.52) |
| Critical | 167 (52.35) | 251 (48.64) | 136 (42.11) | 226 (42.48) |
Patients in our primary biomarker analysis cohort (Included) vs all patients from the original Adaptive COVID-19 Treatment Trial 1 (Total). Data are presented as No. (%) unless noted otherwise.
aNational Institute of Allergy and Infectious Diseases categorization of COVID-19 disease severity.
bModerate/severe disease is a combined subgroup of ordinal scales 4 and 5. Critical disease is a combined subgroup of ordinal scales 6 and 7.